Latest Neurofibrillary tangle Stories
TauRx Publishes Positive Results of Phase II Clinical Trial in the Journal of Alzheimer's Disease ABERDEEN, Scotland and SINGAPORE, Jan.
MORGANTOWN, W.Va., Aug.
Much of the debate in Alzheimer's disease (AD) has focused on whether the protein amyloid-beta or the tau protein is the symptom or the cause of the disease.
A study in mice shows how a breakdown of the brain's blood vessels may amplify or cause problems associated with Alzheimer's disease.
The Capital Institute for Neurosciences, part of Capital Health, Hopewell Township, New Jersey, launches new program to treat Alzheimer's disease and other cognitive disorders.
- totally perplexed and mixed up.